DOCSLIB.ORG

SMARCB1 Deficiency Integrates Epigenetic Signals to Oncogenic Gene Expression Program Maintenance in Human Acute Myeloid Leukemia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Published OnlineFirst February 26, 2018; DOI: 10.1158/1541-7786.MCR-17-0493 Chromatin, Epigenetics and RNA Regulation Molecular Cancer Research SMARCB1 Deficiency Integrates Epigenetic Signals to Oncogenic Gene Expression Program Maintenance in Human Acute Myeloid Leukemia Shankha Subhra Chatterjee1, Mayukh Biswas1, Liberalis Debraj Boila1, Debasis Banerjee2, and Amitava Sengupta1 Abstract SWI/SNF is an evolutionarily conserved multi-subunit chroma- AML blasts, and loss-of-function studies confirmed transcriptional tin remodeling complex that regulates epigenetic architecture and regulation of Rac GTPase guanine nucleotide exchange factors cellular identity. Although SWI/SNF genes are altered in approx- (GEF) by SMARCB1. Mechanistically, loss of SMARCB1 increased D imately 25% of human malignancies, evidences showing their recruitment of SWI/SNF and associated histone acetyltransferases involvement in tumor cell–autonomous chromatin regulation (HAT) to target loci, thereby promoting H3K27Ac and gene and transcriptional plasticity are limiting. This study demonstrates expression. Together, SMARCB1 deficiency induced GEFs for Rac that human primary acute myeloid leukemia (AML) cells exhibit GTPase activation and augmented AML cell migration and sur- near complete loss of SMARCB1 (BAF47 or SNF5/INI1) and vival. Collectively, these findings highlight tumor suppressor role D D SMARCD2 (BAF60B) associated with nucleation of SWI/SNF . of SMARCB1 and illustrate SWI/SNF function in maintaining an D SMARCC1 (BAF155), an intact core component of SWI/SNF , oncogenic gene expression program in AML. colocalized with H3K27Ac to target oncogenic loci in primary D AML cells. Interestingly, gene ontology (GO) term and pathway Implications: Loss of SMARCB1 in AML associates with SWI/SNF analysis suggested that SMARCC1 occupancy was enriched on nucleation, which in turn promotes Rac GTPase GEF expression, genes regulating Rac GTPase activation, cell trafficking, and AML- Rac activation, migration, and survival of AML cells, highlighting D associated transcriptional dysregulation. Transcriptome profiling SWI/SNF downstream signaling as important molecular regula- revealed that expression of these genes is upregulated in primary tor in AML. Mol Cancer Res; 16(5); 791–804. Ó2018 AACR. Introduction not always inform transcriptional dependencies embedded in tumorigenesis. SWI/SNF (BAF) chromatin remodelers are evolutionarily con- Emerging evidences indicate that SWI/SNF subunits critically served, large (2 MDa) multi-protein complexes, which utilize regulate murine hematopoiesis. Recent studies have shown that energy derived from ATP hydrolysis to mobilize nucleosomes (1). SMARCD2 mediates granulopoiesis through CEBPe-dependent SWI/SNF core components include SMARCB1 (BAF47, SNF5 or mechanism (5, 6). Actl6a (BAF53a) plays essential role in hemato- INI1), SMARCC1/SMARCC2 (BAF155 and BAF170), and one of poietic stem cell (HSC) function (7). Mutant allele of Arid1a the mutually exclusive ATPase subunits, SMARCA4 (BRG1) and (BAF250a) determines pool size of fetal liver HSC populations SMARCA2 (BRM). SWI/SNF complexes often include cell type– (8). In addition, SWI/SNF was also implicated in murine leuke- specific, lineage-restricted subunits, and play important roles in mia development. SMARCA4 was shown to regulate proliferation pluripotency and cellular reprogramming (1, 2). Cancer genome of murine leukemic cells (9, 10). SMARCB1 plays tumor sup- sequencing studies have identified SWI/SNF complexes as one of pressor role in several cancers, and frequent deletion of SMARCB1 the most commonly mutated (25%) chromatin modulators in is observed in chronic myeloid leukemia patients (11). Loss of human cancer (3, 4). However, mutational profiling alone may Smarcb1 in vivo leads to fully penetrant malignant rhabdoid tumors (12, 13). Rac GTPases belong to small Rho GTPase family and are 1 Stem Cell & Leukemia Lab, Cancer Biology & Inflammatory Disorder Division, involved in regulation of a diverse array of cellular functions CSIR-Indian Institute of Chemical Biology, Translational Research Unit of including cell proliferation, survival, adhesion, migration, actin Excellence (TRUE), Salt Lake, Kolkata, West Bengal, India. 2Clinical Hematology, Park Clinic, Gorky Terrace, Kolkata, West Bengal, India. assembly, and transcriptional activation (14, 15). Similar to Ras superfamily proteins, Rac GTPases cycle between inactive GDP- Note: Supplementary data for this article are available at Molecular Cancer Research Online (http://mcr.aacrjournals.org/). bound and active GTP-bound conformations, regulated by spe- cific guanine nucleotide exchange factors (GEF), to transduce S.S. Chatterjee and M. Biswas contributed equally to this article. signals to effector proteins (14). Recent studies have suggested Corresponding Author: Amitava Sengupta, CSIR-Indian Institute of Chemical that Rac GTPases play integral roles in myeloid leukemia cell Biology, Kolkata 700091, India. Phone: 9133-2473-0492; Fax: 9133-2473-5197; homing, engraftment, survival, and trafficking within the bone E-mail: [email protected] marrow microenvironment (15–18). Attenuation of Rac GTPase doi: 10.1158/1541-7786.MCR-17-0493 signaling in synergy with Bcl-2 inhibition has been shown as a Ó2018 American Association for Cancer Research. modality for combination targeted therapy in MLL-AF9 leukemia www.aacrjournals.org 791 Downloaded from mcr.aacrjournals.org on September 28, 2021. © 2018 American Association for Cancer Research. Published OnlineFirst February 26, 2018; DOI: 10.1158/1541-7786.MCR-17-0493 Chatterjee et al. (19). Myeloid leukemia cells are characterized with elevated Rac and the integrity was assessed on a 0.8% Agarose Gel. Genomic GTP level; however, molecular regulation of Rac activation in DNA with OD260/OD280 >1.8 and OD260/OD230 1.3 was leukemia pathophysiology remains incompletely understood. used for microarray experiments. DNA was considered to be of Here we identify that in human primary acute myeloid good quality when a single clear band was seen when run against a leukemia (AML) cells, SMARCB1 deficiency associates with reference ladder. A total of 0.5 mg of DNA in 10.1 mL was taken into D nucleation of SWI/SNF . SMARCC1, an intact core component a microfuge tube and digestion master mix containing restriction D of SWI/SNF , colocalized with H3K27Ac to target tumor onco- enzymes (Alu I, 5U and Rsa I, 5U) was added. The samples were genic loci, including Rac GTPase GEFs,inAMLcells.Lossof incubated at 37C for 2 hours followed by heat inactivation of D SMARCB1 induced recruitment of SWI/SNF and associated enzymes at 65C for 20 minutes. Samples were labeled using histone acetyltransferases (HAT) to target GEFs for Rac GTPase Agilent sure tag DNA Labeling Kit (catalog no: 5190-3399). activation and promoted AML cell migration. Collectively, Control samples were labeled with Cy3 and test sample with these findings highlight tumor suppressor role of SMARCB1 Cy5. The labeled samples were cleaned up using Amicon Ultra D and illustrate SWI/SNF function in maintaining an oncogenic columns 30-kDa size exclusion filter. DNA yield and incorpo- gene expression program in AML. ration of labeled dye (specific activity) was measured using NanoDrop spectrophotometer. One micrograms each of Cy3- Materials and Methods and Cy5-labeled sample was added with human cot-1 DNA (catalog no. 5190-3393), Agilent aCGH/CoC Blocking agent (part Patient cohort number: 5188-6416), and hybridization buffer (part number: Human AML (n ¼ 67) bone marrow aspirates (1–2 mL each) 5188-6420). The labeled samples in above hybridization mix were obtained from Park Clinic, Kolkata from untreated, freshly were denatured at 95C for 3 minutes and were incubated at 37C diagnosed patients after written, informed consent according to for 30 minutes. The samples were then hybridized at 65C for 24 Institutional Human Ethics Committee (HEC) approval and hours. After hybridization, the slides were washed using Agilent following Indian Institute of Chemical Biology (CSIR-IICB) Insti- aCGH Wash Buffer1 (Agilent Technologies, part number 5188- tutional Review Board (IRB) set guidelines. Sample collection was 5221) at room temperature for 5 minutes and Agilent aCGH Wash part of routine diagnosis and the inclusion criterion for this study Buffer 2 (Agilent Technologies, part number 5188-5222) at 37C was histopathologic confirmation of bone marrow aspirates or for 1 minute. The slides were then washed with acetonitrile (part biopsies, karyotyping, and immunophenotypic analyses (20). number: A2094) for 10 seconds. The microarray slides were Bone marrow aspirates were also collected from age-matched scanned using Agilent Scanner (Agilent Technologies, part num- normal individuals (n ¼ 6) after informed consent, who turned ber G2600D). Image analysis was performed using Agilent Fea- out to be pathologically negative for AML (20). Individual case ture Extraction software, feature extracted raw data was analyzed information is presented in Supplementary Tables S1 and S2. using Agilent Genomic Workbench 7.0 software. The data were Umbilical cord blood samples (40 mL each) were obtained from normalized using Lowess normalization. Significant regions hav- Deb Shishu Nursing Home (Howrah, West Bengal, India) from ing amplification and deletions were identified among each of the term pregnancies after written, informed consent according to samples. Genomic view and chromosome view of the amplifica- CSIR-IICB HEC approval and following IRB set guidelines.
Recommended publications
  • SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ

    SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ

    Published OnlineFirst April 10, 2013; DOI: 10.1158/1535-7163.MCT-13-0005 Molecular Cancer Cancer Therapeutics Insights Therapeutics SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ Monica Brenca1, Sabrina Rossi3, Erica Lorenzetto1, Elena Piccinin1, Sara Piccinin1, Francesca Maria Rossi2, Alberto Giuliano1, Angelo Paolo Dei Tos3, Roberta Maestro1, and Piergiorgio Modena1 Abstract Epithelioid sarcoma is a rare soft tissue neoplasm that usually arises in the distal extremities of young adults. Epithelioid sarcoma presents a high rate of recurrences and metastases and frequently poses diagnostic dilemmas. We previously reported loss of tumor suppressor SMARCB1 protein expression and SMARCB1 gene deletion in the majority of epithelioid sarcoma cases. Unfortunately, no appropriate preclinical models of such genetic alteration in epithelioid sarcoma are available. In the present report, we identified lack of SMARCB1 protein due to a homozygous deletion of exon 1 and upstream regulatory region in epithelioid sarcoma cell line VAESBJ. Restoration of SMARCB1 expression significantly affected VAESBJ cell proliferation, anchorage-independent growth, and cell migration properties, thus supporting the causative role of SMARCB1 loss in epithelioid sarcoma pathogenesis. We investigated the translational relevance of this genetic back- ground in epithelioid sarcoma and showed that SMARCB1 ectopic expression significantly augmented VAESBJ sensitivity to gamma irradiation and acted synergistically with flavopiridol treatment. In VAESBJ, both activated ERBB1/EGFR and HGFR/MET impinged on AKT and ERK phosphorylation. We showed a synergistic effect of combined inhibition of these 2 receptor tyrosine kinases using selective small-molecule inhibitors on cell proliferation. These observations provide definitive support to the role of SMARCB1 inactivation in the pathogenesis of epithelioid sarcoma and disclose novel clues to therapeutic approaches tailored to SMARCB1-negative epithelioid sarcoma.
  • Integrase Interactor 1 (INI-1) Deficient Renal Cell Carcinoma

    Integrase Interactor 1 (INI-1) Deficient Renal Cell Carcinoma

    Open Access Case Report DOI: 10.7759/cureus.13082 Integrase Interactor 1 (INI-1) Deficient Renal Cell Carcinoma Manpreet Singh 1 , Harkirat Singh 1 , Benjamin Hambro 1 , Jasleen Kaur 1 , Ravi Rao 2 1. Internal Medicine, St Agnes Medical Center, Fresno, USA 2. Hematology and Oncology, St Agnes Medical Center, Fresno, USA Corresponding author: Manpreet Singh, [email protected] Abstract Members of the SWItch/sucrose nonfermentable (SWI-SNF) family, including SWI/SNF related, matrix- associated, actin-dependent regulator of chromatin, subfamily A, member 4 (SMARCA4), SWI/SNF related, matrix‐associated, actin‐dependent regulator of chromatin, subfamily B member 1 (SMARCB1)/integrase interactor 1 (INI-1) are known tumor suppressor genes. Interactions between SMARCB1/INI-1 and key protein components in various cellular pathways are related to tumor progression and proliferation. SMARCB1/INI-1 protein was undetectable in rhabdoid tumor cells, whereas non-tumorous cells express the SMARCB1/INI-1 genes. Germline and sporadic mutations of several genes encoding for proteins in this complex are known to cause a spectrum of cancers, usually with sarcomatoid features which include a very aggressive renal medullary carcinoma. We report a case of a 29-year-old male who presented with SMARCA4 deficient renal tumor with a very aggressive clinical behavior which ultimately led to his death. Categories: Nephrology, Oncology Keywords: renal medullary carcinoma, ini-1, renal cell carcinoma, swi/snf, smarcb1, integrase interactor 1 Introduction Renal medullary carcinoma is a rare and very aggressive malignancy affecting young adults with rare cases in patients with sickle cell disease or trait [1]. The tumor arises predominantly in the renal medulla and exhibits a variety of growth patterns including reticular, solid, tubular, trabecular, cribriform, sarcomatoid, and micropapillary [1].
  • Bioinformatics Applications Through Visualization of Variations on Protein

    Bioinformatics Applications Through Visualization of Variations on Protein

    1 Bioinformatics applications through visualization of variations on protein structures, comparative functional genomics, and comparative modeling for protein structure studies A dissertation presented by Alper Uzun to The Department of Biology In partial fulfillment of the requirements for the degree of Doctor of Philosophy in the field of Biology Northeastern University Boston, Massachusetts July 2009 2 ©2009 Alper Uzun ALL RIGHTS RESERVED 3 Bioinformatics applications through visualization of variations on protein structures, comparative functional genomics, and comparative modeling for protein structure studies by Alper Uzun ABSTRACT OF DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biology in the Graduate School of Arts and Sciences of Northeastern University, July, 2009 4 Abstract The three-dimensional structure of a protein provides important information for understanding and answering many biological questions in molecular detail. The rapidly growing number of sequenced genes and related genomic information is intensively accumulating in the biological databases. It is significantly important to combine biological data and developing bioinformatics tools while information of protein sequences, structures and DNA sequences are exponentially growing. On the other hand, especially the number of known protein sequences is much larger than the number of experimentally solved protein structures. However the experimental methods cannot always be applied or protein structures
  • Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Co-Regulator in Invasive 6 Lobular Carcinoma of the Breast 7 8 Evelyn K

    Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Co-Regulator in Invasive 6 Lobular Carcinoma of the Breast 7 8 Evelyn K

    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.16.423142; this version posted December 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 Running Title: MDC1 co-regulates ER in ILC 2 3 Research article 4 5 Mediator of DNA damage checkpoint 1 (MDC1) is a novel estrogen receptor co-regulator in invasive 6 lobular carcinoma of the breast 7 8 Evelyn K. Bordeaux1+, Joseph L. Sottnik1+, Sanjana Mehrotra1, Sarah E. Ferrara2, Andrew E. Goodspeed2,3, James 9 C. Costello2,3, Matthew J. Sikora1 10 11 +EKB and JLS contributed equally to this project. 12 13 Affiliations 14 1Dept. of Pathology, University of Colorado Anschutz Medical Campus 15 2Biostatistics and Bioinformatics Shared Resource, University of Colorado Comprehensive Cancer Center 16 3Dept. of Pharmacology, University of Colorado Anschutz Medical Campus 17 18 Corresponding author 19 Matthew J. Sikora, PhD.; Mail Stop 8104, Research Complex 1 South, Room 5117, 12801 E. 17th Ave.; Aurora, 20 CO 80045. Tel: (303)724-4301; Fax: (303)724-3712; email: [email protected]. Twitter: 21 @mjsikora 22 23 Authors' contributions 24 MJS conceived of the project. MJS, EKB, and JLS designed and performed experiments. JLS developed models 25 for the project. EKB, JLS, SM, and AEG contributed to data analysis and interpretation. SEF, AEG, and JCC 26 developed and performed informatics analyses. MJS wrote the draft manuscript; all authors read and revised the 27 manuscript and have read and approved of this version of the manuscript.
  • Genomic and Expression Profiling of Chromosome 17 in Breast Cancer Reveals Complex Patterns of Alterations and Novel Candidate Genes

    Genomic and Expression Profiling of Chromosome 17 in Breast Cancer Reveals Complex Patterns of Alterations and Novel Candidate Genes

    [CANCER RESEARCH 64, 6453–6460, September 15, 2004] Genomic and Expression Profiling of Chromosome 17 in Breast Cancer Reveals Complex Patterns of Alterations and Novel Candidate Genes Be´atrice Orsetti,1 Me´lanie Nugoli,1 Nathalie Cervera,1 Laurence Lasorsa,1 Paul Chuchana,1 Lisa Ursule,1 Catherine Nguyen,2 Richard Redon,3 Stanislas du Manoir,3 Carmen Rodriguez,1 and Charles Theillet1 1Ge´notypes et Phe´notypes Tumoraux, EMI229 INSERM/Universite´ Montpellier I, Montpellier, France; 2ERM 206 INSERM/Universite´ Aix-Marseille 2, Parc Scientifique de Luminy, Marseille cedex, France; and 3IGBMC, U596 INSERM/Universite´Louis Pasteur, Parc d’Innovation, Illkirch cedex, France ABSTRACT 17q12-q21 corresponding to the amplification of ERBB2 and collinear genes, and a large region at 17q23 (5, 6). A number of new candidate Chromosome 17 is severely rearranged in breast cancer. Whereas the oncogenes have been identified, among which GRB7 and TOP2A at short arm undergoes frequent losses, the long arm harbors complex 17q21 or RP6SKB1, TBX2, PPM1D, and MUL at 17q23 have drawn combinations of gains and losses. In this work we present a comprehensive study of quantitative anomalies at chromosome 17 by genomic array- most attention (6–10). Furthermore, DNA microarray studies have comparative genomic hybridization and of associated RNA expression revealed additional candidates, with some located outside current changes by cDNA arrays. We built a genomic array covering the entire regions of gains, thus suggesting the existence of additional amplicons chromosome at an average density of 1 clone per 0.5 Mb, and patterns of on 17q (8, 9). gains and losses were characterized in 30 breast cancer cell lines and 22 Our previous loss of heterozygosity mapping data pointed to the primary tumors.
  • Loss of Integrase Interactor 1 (INI1) Expression in a Subset of Differentiated Thyroid Cancer

    Loss of Integrase Interactor 1 (INI1) Expression in a Subset of Differentiated Thyroid Cancer

    diagnostics Article Loss of Integrase Interactor 1 (INI1) Expression in a Subset of Differentiated Thyroid Cancer Kung-Chen Ho 1, Jie-Jen Lee 1, Chi-Hsin Lin 2,3, Ching-Hsiang Leung 4 and Shih-Ping Cheng 1,5,* 1 Department of Surgery, MacKay Memorial Hospital and Mackay Medical College, Taipei 104215, Taiwan; [email protected] (K.-C.H.); [email protected] (J.-J.L.) 2 Department of Medical Research, MacKay Memorial Hospital, Taipei 104215, Taiwan; [email protected] 3 Department of Bioscience Technology, Chung Yuan Christian University, Taoyuan City 320314, Taiwan 4 Division of Endocrinology and Metabolism, Department of Internal Medicine, MacKay Memorial Hospital and Mackay Medical College, Taipei 104215, Taiwan; [email protected] 5 Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110301, Taiwan * Correspondence: [email protected]; Tel.: +886-2-2543-3535 Received: 19 April 2020; Accepted: 2 May 2020; Published: 5 May 2020 Abstract: Alterations in the switching defective/sucrose non-fermenting (SWI/SNF) chromatin-remodeling complex are enriched in advanced thyroid cancer. Integrase interactor 1 (INI1), encoded by the SMARCB1 gene on the long arm of chromosome 22, is one of the core subunits of the SWI/SNF complex. INI1 immunohistochemistry is frequently used for the diagnosis of malignant rhabdoid neoplasms. In the present study, we found normal and benign thyroid tissues generally had diffusely intense nuclear immunostaining. Loss of INI1 immunohistochemical expression was observed in 8% of papillary thyroid cancer and 30% of follicular thyroid cancer. Furthermore, loss of INI1 expression was associated with extrathyroidal extension (p < 0.001) and lymph node metastasis (p = 0.038).
  • Renal Medullary Carcinomas Depend Upon SMARCB1 Loss And

    Renal Medullary Carcinomas Depend Upon SMARCB1 Loss And

    RESEARCH ARTICLE Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition Andrew L Hong1,2,3, Yuen-Yi Tseng3, Jeremiah A Wala3, Won-Jun Kim2, Bryan D Kynnap2, Mihir B Doshi3, Guillaume Kugener3, Gabriel J Sandoval2,3, Thomas P Howard2, Ji Li2, Xiaoping Yang3, Michelle Tillgren2, Mahmhoud Ghandi3, Abeer Sayeed3, Rebecca Deasy3, Abigail Ward1,2, Brian McSteen4, Katherine M Labella2, Paula Keskula3, Adam Tracy3, Cora Connor5, Catherine M Clinton1,2, Alanna J Church1, Brian D Crompton1,2,3, Katherine A Janeway1,2, Barbara Van Hare4, David Sandak4, Ole Gjoerup2, Pratiti Bandopadhayay1,2,3, Paul A Clemons3, Stuart L Schreiber3, David E Root3, Prafulla C Gokhale2, Susan N Chi1,2, Elizabeth A Mullen1,2, Charles WM Roberts6, Cigall Kadoch2,3, Rameen Beroukhim2,3,7, Keith L Ligon2,3,7, Jesse S Boehm3, William C Hahn2,3,7* 1Boston Children’s Hospital, Boston, United States; 2Dana-Farber Cancer Institute, Boston, United States; 3Broad Institute of Harvard and MIT, Cambridge, United States; 4Rare Cancer Research Foundation, Durham, United States; 5RMC Support, North Charleston, United States; 6St. Jude Children’s Research Hospital, Memphis, United States; 7Brigham and Women’s Hospital, Boston, United States Abstract Renal medullary carcinoma (RMC) is a rare and deadly kidney cancer in patients of African descent with sickle cell trait. We have developed faithful patient-derived RMC models and using whole-genome sequencing, we identified loss-of-function intronic fusion events in one SMARCB1 allele with concurrent loss of the other allele. Biochemical and functional characterization of these models revealed that RMC requires the loss of SMARCB1 for survival.
  • Identification of a Core Member of the SWI/SNF Complex, BAF155/SMARCC1, As a Human Tumor Suppressor Gene

    Identification of a Core Member of the SWI/SNF Complex, BAF155/SMARCC1, As a Human Tumor Suppressor Gene

    RESEARCH PAPER Epigenetics 6:12, 1444-1453; December 2011; © 2011 Landes Bioscience Identification of a core member of the SWI/SNF complex, BAF155/SMARCC1, as a human tumor suppressor gene Jessica DelBove,1,6 Gary Rosson,2,7 Matthew Strobeck,3 Jianguang Chen,4 Trevor K. Archer,4 Weidong Wang,5 Erik S. Knudsen3 and Bernard E. Weissman1,2,* 1Department of Pathology and Laboratory Medicine; 2University of North Carolina-Lineberger Comprehensive Cancer Center; 7Department of Genetics; University of North Carolina; Chapel Hill, NC USA; 3Department of Cancer Biology and the Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA; 4Chromatin and Gene Expression Section; Laboratory of Molecular Carcinogenesis; National Institute of Environmental Health Sciences; National Institutes of Health; Research Triangle Park, NC USA; 5Laboratory of Genetics; National Institute on Aging; National Institutes of Health; Baltimore, MD USA; 6Department of Hematology; University of Utah School of Medicine; Salt Lake City, UT USA Key words: SWI/SNF, BAF155, SMARCC1, tumor suppressor gene, cancer epigenetics Recent studies have established that two core members of the SWI/SNF chromatin remodeling complex, BRG1 and SNF5/ INI1, possess tumor-suppressor activity in human and mouse cancers. While the third core member, BAF155, has been implicated by several studies as having a potential role in tumor development, direct evidence for its tumor suppressor activity has remained lacking. Therefore, we screened for BAF155 deficiency in a large number of human tumor cell lines. We identified two cell lines, the SNUC2B colon carcinoma and the SKOV3 ovarian carcinoma, displaying a complete loss of protein expression while maintaining normal levels of mRNA expression.
  • Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories

    Association of Gene Ontology Categories with Decay Rate for Hepg2 Experiments These Tables Show Details for All Gene Ontology Categories

    Supplementary Table 1: Association of Gene Ontology Categories with Decay Rate for HepG2 Experiments These tables show details for all Gene Ontology categories. Inferences for manual classification scheme shown at the bottom. Those categories used in Figure 1A are highlighted in bold. Standard Deviations are shown in parentheses. P-values less than 1E-20 are indicated with a "0". Rate r (hour^-1) Half-life < 2hr. Decay % GO Number Category Name Probe Sets Group Non-Group Distribution p-value In-Group Non-Group Representation p-value GO:0006350 transcription 1523 0.221 (0.009) 0.127 (0.002) FASTER 0 13.1 (0.4) 4.5 (0.1) OVER 0 GO:0006351 transcription, DNA-dependent 1498 0.220 (0.009) 0.127 (0.002) FASTER 0 13.0 (0.4) 4.5 (0.1) OVER 0 GO:0006355 regulation of transcription, DNA-dependent 1163 0.230 (0.011) 0.128 (0.002) FASTER 5.00E-21 14.2 (0.5) 4.6 (0.1) OVER 0 GO:0006366 transcription from Pol II promoter 845 0.225 (0.012) 0.130 (0.002) FASTER 1.88E-14 13.0 (0.5) 4.8 (0.1) OVER 0 GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolism3004 0.173 (0.006) 0.127 (0.002) FASTER 1.28E-12 8.4 (0.2) 4.5 (0.1) OVER 0 GO:0006357 regulation of transcription from Pol II promoter 487 0.231 (0.016) 0.132 (0.002) FASTER 6.05E-10 13.5 (0.6) 4.9 (0.1) OVER 0 GO:0008283 cell proliferation 625 0.189 (0.014) 0.132 (0.002) FASTER 1.95E-05 10.1 (0.6) 5.0 (0.1) OVER 1.50E-20 GO:0006513 monoubiquitination 36 0.305 (0.049) 0.134 (0.002) FASTER 2.69E-04 25.4 (4.4) 5.1 (0.1) OVER 2.04E-06 GO:0007050 cell cycle arrest 57 0.311 (0.054) 0.133 (0.002)
  • Inactivation of the PBRM1 Tumor Suppressor Gene Amplifies

    Inactivation of the PBRM1 Tumor Suppressor Gene Amplifies

    Inactivation of the PBRM1 tumor suppressor gene − − amplifies the HIF-response in VHL / clear cell renal carcinoma Wenhua Gaoa, Wei Lib,c, Tengfei Xiaoa,b,c, Xiaole Shirley Liub,c, and William G. Kaelin Jr.a,d,1 aDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115; bCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215; cDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA 02115; and dHoward Hughes Medical Institute, Chevy Chase, MD 20815 Contributed by William G. Kaelin, Jr., December 1, 2016 (sent for review October 31, 2016; reviewed by Charles W. M. Roberts and Ali Shilatifard) Most clear cell renal carcinomas (ccRCCs) are initiated by somatic monolayer culture and in soft agar (10). These effects were not, inactivation of the VHL tumor suppressor gene. The VHL gene prod- however, proven to be on-target, and were not interrogated in uct, pVHL, is the substrate recognition unit of an ubiquitin ligase vivo. As a step toward understanding the role of BAF180 in that targets the HIF transcription factor for proteasomal degrada- ccRCC, we asked whether BAF180 participates in the canonical tion; inappropriate expression of HIF target genes drives renal car- PBAF complex in ccRCC cell lines and whether loss of BAF180 cinogenesis. Loss of pVHL is not sufficient, however, to cause ccRCC. measurably alters ccRCC behavior in cell culture and in mice. Additional cooperating genetic events, including intragenic muta- tions and copy number alterations, are required.
  • SMARCE1 Mutations in Pediatric Clear Cell Meningioma: Case Report

    SMARCE1 Mutations in Pediatric Clear Cell Meningioma: Case Report

    PEDIATRICS CASE REPORT J Neurosurg Pediatr 16:296–300, 2015 SMARCE1 mutations in pediatric clear cell meningioma: case report Linton T. Evans, MD,1 Jack Van Hoff, MD,2,4,5 William F. Hickey, MD,3,4 Miriam J. Smith, PhD,6 D. Gareth Evans, MD,6 William G. Newman, MD, PhD,6 and David F. Bauer, MD1,2,4,5 1Section of Neurosurgery, 2Department of Pediatrics, and 3Department of Pathology, Dartmouth-Hitchcock Medical Center; 4Norris Cotton Cancer Center; 5Children’s Hospital at Dartmouth-Hitchcock, Lebanon, New Hampshire; and 6Manchester Centre for Genomic Medicine, Manchester Academic Health Sciences Centre (MAHSC), St. Mary’s Hospital, University of Manchester, United Kingdom Clear cell meningioma (CCM) is an uncommon variant of meningioma. The authors describe a case of a pediatric CCM localized to the lumbar spine. After resection, sequencing revealed an inactivating mutation in the SWI/SNF chromatin remodeling complex subunit SMARCE1, with loss of the second allele in the tumor. The authors present a literature review of this mutation that is associated with CCM and a family history of spine tumors. http://thejns.org/doi/abs/10.3171/2015.3.PEDS14417 KEY WORDS clear cell meningioma; SMARCE1; SWI/SNF; oncology LEAR cell meningioma (CCM) is a rare histopatho- of a SMARCE1 mutation and loss of heterozygosity in logical variant originally described in 1990. This a 3-year-old boy with an intraspinal CCM and a relative subtype is estimated to account for less than 1% of with a known spinal tumor. meningiomasC but is frequently difficult to treat. Despite a benign histological appearance, these tumors exhibit Case Report aggressive behavior with up to 60% recurring following resection.
  • 3D Interactions with the Growth Hormone Locus in Cellular Signalling and Cancer-Related Pathways

    3D Interactions with the Growth Hormone Locus in Cellular Signalling and Cancer-Related Pathways

    64 4 Journal of Molecular L Jain et al. 3D interactions with the GH locus 64:4 209–222 Endocrinology RESEARCH 3D interactions with the growth hormone locus in cellular signalling and cancer-related pathways Lekha Jain, Tayaza Fadason, William Schierding, Mark H Vickers, Justin M O’Sullivan and Jo K Perry Liggins Institute, University of Auckland, Auckland, New Zealand Correspondence should be addressed to J K Perry or J M O’Sullivan: [email protected] or [email protected] Abstract Growth hormone (GH) is a peptide hormone predominantly produced by the anterior Key Words pituitary and is essential for normal growth and metabolism. The GH locus contains f growth hormone locus five evolutionarily related genes under the control of an upstream locus control region f GH1 that coordinates tissue-specific expression of these genes. Compromised GH signalling f genome and genetic variation in these genes has been implicated in various disorders including f chromosome capture cancer. We hypothesised that regulatory regions within the GH locus coordinate f cancer expression of a gene network that extends the impact of the GH locus control region. We used the CoDeS3D algorithm to analyse 529 common single nucleotide polymorphisms (SNPs) across the GH locus. This algorithm identifies colocalised Hi-C and eQTL associations to determine which SNPs are associated with a change in gene expression at loci that physically interact within the nucleus. One hundred and eighty-one common SNPs were identified that interacted with 292 eGenes across 48 different tissues. One hundred and forty-five eGenes were regulated intrans .